[New medication combines osteo-anabolic and anti-resorptive effects. Double strategy against osteoporosis].
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000517:prevention & control; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D010919:Placebos; D051381:Rats; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D009942:Organometallic Compounds; D010919:Placebos; D013876:Thiophenes; C081587:strontium ranelate